Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jianming He

Showing results (51-60 of 70) with videos related to

Pageof 7
Sort By:
Ejhaem|July 18, 2022
Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D-VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant-eligible patients with newly diagnosed multiple myeloma, using propensity score matchingPhilippe Moreau, Cyrille Hulin, Sonja Zweegman, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 18, 2025
Real-World Treatment Patterns and Outcomes in Patients With Lenalidomide-Refractory Multiple Myeloma With 1 to 3 Prior Lines: SEER-Medicare DatabaseBinod Dhakal, Jinghua He, Jordan M Schecter, et al.
Blood Advances|August 7, 2024
Real-world treatment patterns and outcomes in relapsed/refractory multiple myeloma (1-3 prior lines): Flatiron databaseBinod Dhakal, Hermann Einsele, Jordan M Schecter, et al.
BMC Cancer|November 11, 2020
Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myelomaRafael Fonseca, Saad Z Usmani, Maneesha Mehra, et al.
Advances in Therapy|June 28, 2022
Correction to: Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysisThierry Facon, Jesús San-Miguel, Meletios A Dimopoulos, et al.
Advances in Therapy|March 5, 2022
Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysisThierry Facon, Jesús San-Miguel, Meletios A Dimopoulos, et al.
Clinical Hematology International|December 29, 2025
Real-world outcomes in patients with relapsed and refractory multiple myeloma with prior proteasome inhibitor and lenalidomide exposure: A single-center study in SwedenVincent Luong, Muhammad Kashif, Katarina Uttervall, et al.
British Journal of Haematology|February 19, 2020
Comparison of efficacy from two different dosing regimens of bortezomib: an exposure-response analysisDolly A Parasrampuria, Jianming He, Liping Zhang, et al.
Stem Cell Research & Therapy|November 1, 2025
The CBS/H2S axis regulates intestinal stem cell homeostasis and radiation-induced intestinal damageTianyu Wu, Zhiyuan Zheng, Jiong Ren, et al.
The Oncologist|April 24, 2022
Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple MyelomaAndrzej J Jakubowiak, Shaji Kumar, Rohan Medhekar, et al.
Pageof 7

Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
Ejhaem|July 18, 2022
Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D-VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant-eligible patients with newly diagnosed multiple myeloma, using propensity score matchingPhilippe Moreau, Cyrille Hulin, Sonja Zweegman, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 18, 2025
Real-World Treatment Patterns and Outcomes in Patients With Lenalidomide-Refractory Multiple Myeloma With 1 to 3 Prior Lines: SEER-Medicare DatabaseBinod Dhakal, Jinghua He, Jordan M Schecter, et al.
Blood Advances|August 7, 2024
Real-world treatment patterns and outcomes in relapsed/refractory multiple myeloma (1-3 prior lines): Flatiron databaseBinod Dhakal, Hermann Einsele, Jordan M Schecter, et al.
BMC Cancer|November 11, 2020
Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myelomaRafael Fonseca, Saad Z Usmani, Maneesha Mehra, et al.
Advances in Therapy|June 28, 2022
Correction to: Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysisThierry Facon, Jesús San-Miguel, Meletios A Dimopoulos, et al.
Advances in Therapy|March 5, 2022
Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysisThierry Facon, Jesús San-Miguel, Meletios A Dimopoulos, et al.
Clinical Hematology International|December 29, 2025
Real-world outcomes in patients with relapsed and refractory multiple myeloma with prior proteasome inhibitor and lenalidomide exposure: A single-center study in SwedenVincent Luong, Muhammad Kashif, Katarina Uttervall, et al.
British Journal of Haematology|February 19, 2020
Comparison of efficacy from two different dosing regimens of bortezomib: an exposure-response analysisDolly A Parasrampuria, Jianming He, Liping Zhang, et al.
Stem Cell Research & Therapy|November 1, 2025
The CBS/H2S axis regulates intestinal stem cell homeostasis and radiation-induced intestinal damageTianyu Wu, Zhiyuan Zheng, Jiong Ren, et al.
The Oncologist|April 24, 2022
Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple MyelomaAndrzej J Jakubowiak, Shaji Kumar, Rohan Medhekar, et al.
Pageof 7